Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- Pharma Might Skirt Market-Price Based Price Cuts in 2017 If Physician Fees Become Taxable
March 3, 2015
- MHLW Won’t Order Novartis to Revise Package Inserts over Delayed ADR Reports, Urges Firms to Inspect Safety Control Regime
March 2, 2015
- PMDA Evaluating Sitagliptin for Risk of Thrombocytopenia
March 2, 2015
- Novartis Slapped with 15 Day Biz Suspension over Flawed ADR Reporting
February 27, 2015
- PAFSC Second Committee Backs Approval of Celgene’s Pomalidomide
February 27, 2015
- Roundtable Discussion for Healthcare Policy for 2035 Kicked Off
February 27, 2015
- MHLW OKs 60 New APIs in 2014, Doubling from Year Ago
February 26, 2015
- MHLW Prods Self-Inspections at Insurance Pharmacies after Medication History Fuss
February 25, 2015
- Drug Price Settlement Rate at 76.2% in December: MHLW
February 24, 2015
- Shelved Decision on Xarelto Recommendation Doesn’t Mean Disapproval: MHLW
February 24, 2015
- New Division for Cancer and Specific Diseases Control to Handle Hepatitis Measures after Reorganization of HSB
February 24, 2015
- Editor’s Pick: Five Healthcare News Headlines for Feb. 9 - 22
February 23, 2015
- Shiozaki Says Annual NHI Price Cuts Could Hit Distributors, Mar Innovation Drive; Ministry to Consider Plan based on Govt’s Economic Blueprint
February 23, 2015
- PAFSC Committee’s Nod for New Xarelto Indication Put on Hold
February 23, 2015
- Drug Dispensing Expenditure Up 1.8% in April-September 2014; Down 4.1 Points from Previous Year
February 23, 2015
- Gilead’s Sofosbuvir Could Join NHI Price List in May If OK’ed by PAFSC Panel on March 5
February 20, 2015
- MHLW Picks 4 Hospitals Eligible for Special Mixed Care Scheme in Tokyo Economic Zone
February 20, 2015
- Panel OKs Intractable Disease Designation of 43 More Diseases
February 19, 2015
- Japan Generic Share at 55% in September 2014: MHLW
February 19, 2015
- Chuikyo Approves 26 Products Including Takecab, Zelboraf for Listing
February 19, 2015
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…